This report was first published by Endpoints News. To see the original version, click here
As the calendar turns from JPM to quarterly reports, earnings bellwether Johnson & Johnson makes its return for 2026. The focus this time? How biopharma will react to a slate of most favored nation deals with the Trump administration.
J&J executives essentially shrugged off any financial impact from its MFN deal that was signed earlier this month, saying it will be “evenly distributed throughout the year.” When combined with fourth-quarter sales that nearly reached $25 billion — up 9.1% from the same period a year earlier — it sets up a strong 2026 for the company, CFO Joseph Wolk said on Wednesday’s investor call.
您已阅读28%（711字），剩余72%（1817字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。